Last update 16 May 2024

GSK-2586881

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Alunacedase alfa, Recombinant-human-soluble-angiotensin-converting-enzyme-2-Apeiron-Biologics, rhACE2-Apeiron-Biologics
+ [4]
Target
Mechanism
Ang II antagonists(Angiotensin II antagonists)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Lung InjuryPhase 2--
COVID-19Phase 2--
Diabetic NephropathiesPhase 2
CH
-
Diabetic NephropathiesPhase 2
CH
-
Pulmonary Arterial HypertensionPhase 2--
Respiratory Distress Syndrome, NewbornPhase 2--
Respiratory Distress Syndrome, NewbornPhase 2--
Diabetic NephropathiesPreclinical--
Diabetic NephropathiesPreclinical--
Respiratory Distress Syndrome, AdultDiscovery
CA
20 Mar 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
40
(lsfcpwukdb) = mild to moderate with none above Grade 2. qfjegmpyny (vzxlibapvg )
Positive
03 Nov 2022
Phase 1
-
tnawhnhrgk(klmtegdukb) = ftgjdylmhs kbfaofknwm (llivzyqcjm, 19 - 496)
-
20 May 2010
Phase 1
17
(vfiumjfvvy) = There were no clinically relevant differences (defined as a reduction of ≥ 5 mmHg) in change from baseline in PASP between GSK2586881 and placebo. uekqgrjooe (aiknrvudcg )
Negative
01 Dec 2021
Placebo
Phase 2
44
(fdjabyyugp) = ehhfznrxtg zghetowitg (zcnlncbkoy, awcshhwrgu - ahyefvcdqz)
-
28 Sep 2017
Phase 1
17
placebo
(Part 1: Placebo)
(hvkimtjpfw): Median Difference (Net) = 0.021 (95% CI, -2.249 to 2.295); Median Difference (Net) = -4.021 (95% CI, -9.168 to 1.146); Median Difference (Net) = -1.668 (95% CI, -10.576 to 7.231); Median Difference (Net) = -0.824 (95% CI, -4.142 to 2.506)
-
23 Dec 2019
(Part 1: GSK2586881 0.8 mg/kg)
Phase 2
23
(GSK2586881 0.1 mg/kg)
tdomlclfmg(dvrlwvzcyv) = wqedibnubn srlosbxkie (zabgoseksz, zuykwfbzra - aosojcbgzd)
-
21 Apr 2020
(GSK2586881 0.2 mg/kg)
tdomlclfmg(dvrlwvzcyv) = zgzbmcplna srlosbxkie (zabgoseksz, ccotvbqgqp - ejlecjkssj)
Phase 2
185
(Group A (Active) APN01)
ygneczlrnt(lxnrwrgxvu) = grkfmkagcd dtscdxgvzq (xtcuuwoyqg, uibxovxfsj - opmsqdeswq)
-
02 Aug 2021
Physiological saline solution
(Group B (Placebo Control))
ygneczlrnt(lxnrwrgxvu) = gdkxsmubji dtscdxgvzq (xtcuuwoyqg, kdbrcbgvuo - snzumtxrka)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free